Almac Discovery: An oncology biotech with an extended reach.
Cell cycle regulators, protein drug conjugates, ubiquitin specific proteases and effectors of the epithelial mesenchymal transition (EMT): All part of the oncology, discovery and early development, pipeline of Almac Discovery.
Our powerful competence in small molecule medicinal chemistry and protein and peptide engineering has enabled Almac Discovery to develop state-of- the-art platforms for both:
• the discovery and validation of inhibitors of ubiquitin specific proteases, a large untapped reservoirs of potential therapeutic targets with biology important to a wide range of potential indications and,
• protein drug conjugates using shark derived binders to enhance tumour penetration.
We have partnering opportunities for cell cycle regulation with our Wee-1 inhibitor a novel approach to tackling the cell cycle by driving division of damaged DNA and also a Phase I EMT programme in development for ovarian cancer in the first instance
Aptus Clinical Ltd
Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.
What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.
Whether you need one-off consultancy support, clinical SOP implementation, expert medical or scientific input on a short or long term basis, or a full trial programme, we’d love to hear from you.
Barrington James are a global staffing and resourcing organisation who specialise in placing niche consultants of all levels in the Biotech and Pharmaceutical industry. We offer both short and long term solutions and can provide adhoc consultancy support as required. Our offices in Europe, USA and APAC means that we can provide a truly global solution and experience in a market you may not know.
All of our team are dedicated market specialists with unrivaled candidate networks and will be on hand in Barcelona to discuss any assistance you may need to aid you getting your product to market. We have proven experience in knowing the difference between working for a big pharma and a new start-up Biotech and will ensure that the people you hire truly understand your business and what you need to succeed.
BioPartner UK is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. It has a membership of core life Science companies that represent British expertise keen to do business overseas. Biopartner leads the UK Delegation to several partnering conferences each year, and through its partnerships, offers discounts to all UK companies with higher rates and benefits to its members.
Cello Health Consulting
Cello Health is organised around three core capabilities - Insight, Consulting and Communications - which allows us to look at complex market challenges through ‘multiple lenses’. This enables us to help healthcare businesses unlock the potential of their assets, brands and organisations in a changing and challenging environment. The formation of Cello Health reflects industry pressure to optimise the potential of molecular assets and demonstrate value, recognises the loss of blockbusters, and the subsequent impact on available resources to bring brands to market. The Cello Health structure gives us a broader view of commercial and clinical success, and enables us to provide a greater depth and breadth of services to help support your critical decision making.
Adrian WalfordVice President Business Development
Jude AbernethyManaging Consultant
Clinical Network Services (UK) Ltd
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Mr Paul CroninDirector
Concept Life Sciences
Concept Life Sciences is a knowledge based, science led business focused on delivering the expertise and capabilities our clients demand. We are a European based contract research organisation of over 600 scientists providing drug discovery, development and analytical services to pharmaceutical and biotechnology clients globally. We can collaborate across all areas of your discovery and development programme as you progress from first concept to the launch of a finished product. Our highly trained scientists will provide support every step of the way from target to lead, lead to candidate and candidate to development.
In discovery research, we provide expert services as individual elements or as a fully integrated discovery project delivering pre-clinical candidates. Our scientists are experienced in complex chemistry (synthesis), pharmacology and pathways analysis. By ensuring our medicinal chemists, our computational chemistry team, our synthetic chemistry and in vitro biology/ADMET departments are always working in step with each other we can accelerate the testing cycle.
Moving through drug development and launch we have one of the widest ranges of analytical equipment available in Europe with specialist materials characterisation, chromatographic and spectroscopic services. Our pre-nomination support package covers comprehensive API characterisation, solubility/permeability/bioavailability determination and pre-formulation screening (excipient/salt/polymorph/crystallisation). We also have API processing capability including lyophilisation and micronisation services. We offer short and long term ICH stability studies, release testing and CMC support. Where required our services are cGMP certified.
In addition, you can trust us to solve issues relating to the safety of compounds or selection of research candidates. We are experts in investigative and mechanistic toxicology, exploratory and discovery toxicology, PK and metabolism and dermal absorption.
Mr Gordon WoodrowVice President - Business Development - Integrated Discovery Services
CTI Clinical Trial and Consulting
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations.
CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific.
Datatrial are a technology-focused business with a mature and elegant EDC system. We also offer a compliant document management solution and data storage. Our vision is to offer end-to-end documents to data and to include everything from discovery through to post marketing information in one easy to search environment. Key to this is making our platform accessible, both financially and from a user perspective, to small and mid-size businesses across a number of therapeutic areas or focuses (medical device, diagnostics and therapeutics).
With headquarters in Newcastle upon Tyne, UK and offices in Boston MA and BioHub at Alderley Park, UK we are very able to support global clinical development programs. Since 1999, we have been serving the pharmaceutical community through our commitment to service and quality in every aspect of the work that we do. With involvement in over 300 clinical trials, across 25 therapeutic areas and with extensive oncology experience we will work with you to develop a software solution that best fits your needs.
Ms Emma BanksCEO
F-star Biotechnology Ltd.
F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to create bispecific antibodies where the second binding site is in the constant Fc region of an antibody. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Bristol-Myers Squibb, Merck Serono and Denali Therapeutics. F-star has currently one programme in the clinic with a second immuno-oncology programme heading toward IND. The Company has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.
F-star’s management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. F-star has raised close to $100M in non-dilutive capital and revenues. The company currently employs over 80 people at its research site in Cambridge, UK.